Andrew McKenzie, PhD
Vice President, Personalized Medicine, Sarah Cannon Research Institute; Scientific Director, Genospace
Dr. McKenzie joined Sarah Cannon in 2015 and serves as the vice president of Sarah Cannon Research Institute’s (SCRI) Personalized Medicine Program. He also serves as the scientific director for Genospace, SCRI's fully-integrated personalized medicine engine.
McKenzie has more than 10 years of basic science and translational research experience in oncology. In his role, Dr. McKenzie is responsible for providing scientific and operational oversight for implementing SCRI’s personalized medicine strategy. He and the personalized medicine program provide scientific, consultative and programmatic services to clinical research investigators, study sponsors, research personnel and other healthcare providers to advance SCRI’s molecular profiling efforts. As scientific director at Genospace, McKenzie is responsible for providing scientific and strategic guidance to data science and product development activities.
Prior to joining SCRI, Dr. McKenzie was a research fellow in the cancer biology department at Vanderbilt University's Vanderbilt-Ingram Cancer Center where he investigated extracellular vesicle trafficking and translational cell biology research. He earned a Bachelor of Science from Shorter College and a Doctor of Philosophy in pharmacology from The University of Vermont where he investigated extracellular matrix remodeling and cell motility.